Lymphocyte Activation Gene 3 Protein Market- Size, Share, Outlook, and Forecast till 2026
Lymphocyte-activation gene 3, also known as LAG-3, is a protein that is has diverse biological effects on the functioning of T cells. This protein was first discovered in 1990. LAG-3 is an immune checkpoint receptor, and is thus used as the target of various drug development programs.
Increasing prevalence of chronic diseases such as cancer and autoimmune diseases such as AIDS are expected to increase the demand for treatment measures. This in turn, is expected to increase demand for lymphocyte-activation gene 3 protein, thus boosting growth of the lymphocyte-activation gene 3 market. Increasing number of pharmaceutical companies are seeking to develop new treatments for cancer and autoimmune disorders is expected to boost growth of the Lymphocyte-activation gene 3 protein market.
Get Sample copy of research report: https://www.worldwidemarketreports.com/sample/196105
Prima BioMed Ltd is a biotechnology company that is engaged in research, development, and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment with its core technologies based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.
The lymphocyte-activation gene 3 market is gaining significant traction, owing to increasing research and development activities by various key players in the market.
F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies—announced successful dosing of the first patient with FS118 in a Phase I clinical trial. FS118 is a first-in-class bispecific antagonist simultaneously targeting LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1), two immune checkpoint molecules involved in tumor growth through attenuation of immune surveillance. FS118 showed potent anti-cancer activity in preclinical models, as recently presented by F-star at the 2018 AACR meeting.
Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/196105
In March 2015, a breakthrough in immunotherapy was recorded when the FDA approved Nivolumab as a second line treatment for metastatic lung squamous carcinoma. Nivolumab was previously known to be indicated for use among patients suffering from melanoma that is either not resectable or had not responded to other therapies.6, 7, 8, 10, not all PD‐1 or PD‐L1 positive patients show positive outcomes through this treatment of anti‐PD‐1 or PD‐L1 monoclonal antibody.
In 2014, GSK successfully was able to receive positive outcomes from its product GSK2831781, an anti LAG-3 drug, which proved to demonstrate positive results among healthy people and patients suffering from plaque psoriasis.
Browse more detail information about Lymphocyte Activation Gene 3 Protein Market Report at: https://www.worldwidemarketreports.com/market-insights/lymphocyte-activation-gene-3-protein-market
Bristol-Myers Squibb, also known as BMS, developed an Anti‐LAG‐3 drug. The company announced in 2017, that it successfully completed its preliminary efficacy trial for BMS-986016—an investigational anti-lymphocyte-activation gene 3 (LAG-3) therapy—in combination with Opdivo (nivolumab) for advanced melanoma. These patients were previously treated with anti-PD-1/PD-L1 therapy, however, showed no progress. While treatment with the new drug helped stop relapse melanoma among these patients. This development in turn, is expected to boost growth of the lymphocyte-activation gene 3 market.
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.
Worldwide Market Reports
Tel: +1 415 871 0703
Visit our Website for More Details: https://www.worldwidemarketreports.com
Visit our new Website: https://industrychronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lymphocyte Activation Gene 3 Protein Market- Size, Share, Outlook, and Forecast till 2026 here
News-ID: 1168664 • Views: 162
More Releases from worldwidemarketreports
What are the different trends in Cash Logistics Market to boost its growth?
WorldwideMarket Reports has announced the addition of the “Cash Logistics Market to 2026”, the report classifies the global Cash Logistics Market in a precise manner to offer unearth valuable, accurate and reliable data insights that help organizations to meet their business objectives and enable growth This report studies the global Cash Logistics market, analyzes and researches the Cash Logistics development status and forecast in United States, EU, Japan, China, India and
Robo-Taxi Market is expected to register a modest increase in the near-term asse …
A robotaxi also known as a self-driving taxi or a driverless taxi, is an autonomous car (SAE automation level 4 or 5) operated for a ridesharing company . The fact of eliminating the need for a human driver or chauffeur, which represents a significant part of the operating costs of that type of services, could make it a very affordable solution for the customers and accelerate the spreading of Transportation-as-a-Service
Life Support Systems Market Expected to Beat Earnings Estimates
A life-support system is the combination of equipment that allows survival in an environment or situation that would not support that life in its absence. It is generally applied to systems supporting human life in situations where the outside environment is hostile, such as in space or underwater, or medical situations where the health of the person is compromised to the extent that the risk of death would be high
Why 2021's ketone market has made young investors ‘excessively optimistic
In chemistry, a ketone is a functional group with the structure R2C=O, where R can be a variety of carbon-containing substituents. Ketones contain a carbonyl group (a carbon-oxygen double bond). The simplest ketone is acetone (R = R' = methyl), with the formula CH3C(O)CH3. Many ketones are of great importance in industry and in biology. Examples include many sugars (ketoses), many steroids (e.g., testosterone), and the solvent acetone. The ketone
More Releases for Lymphocyte
Tumor Infiltrating Lymphocyte (TIL) Market 2021 | Detailed Report
The Tumor Infiltrating Lymphocyte (TIL) research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Tumor Infiltrating Lymphocyte (TIL) research report offers information and thoughtful facts like share, revenue, historical data, and global market share. It also highlights vital aspects like opportunities, driving, product scope, market overview, and driving force. Download FREE
Global Biosimilar Lymphocyte Modulator Market 2021 | Size, Growth, Demand, Oppor …
Get up to 33% off on ALL market research reports at The Business Research Company's holiday sale; buy now! https://www.thebusinessresearchcompany.com/global-market-reports ‘Biosimilar Lymphocyte Modulator Global Market Report 2021 - COVID-19 Growth And Change’ by The Business Research Company is the most comprehensive report available on this market, with analysis of the market’s historic and forecast growth, drivers and restraints causing this, and highlights of the opportunities that companies in the industry can take
Global Tumor Infiltrating Lymphocyte (TIL) Market Huge Growth Opportunity betwee …
LP INFORMATION recently released a research report on the Tumor Infiltrating Lymphocyte (TIL) market analysis and elaborate the industry coverage, current market competitive status, and market outlook and forecast by 2025. Moreover, it categorizes the global Tumor Infiltrating Lymphocyte (TIL) market by key players, product type, applications and regions,etc. The main objective of this market research is to help the readers understand the structure of Tumor Infiltrating Lymphocyte (TIL) market,
Lymphocyte Activation Gene - 3 Protein Market - Size, Share, Outlook, and Opport …
Immune checkpoint receptors such as lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene - 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene - 3 turns off
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or …
Market Research Hub has added a new report tilted "Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2018" to its vast database of market reports. Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or …
ReportsWorldwide has announced the addition of a new report title Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 38 molecules. Out of which approximately 37 molecules are developed by companies